The Impact of AI-Driven Predictive Analytics on Clinical Trial Feasibility Success Rates in 2026

AI-driven predictive analytics compresses clinical trial feasibility from weeks to hours and flags enrolment risk before sites are activated, but it informs the go/no-go decision rather than making it. A June 2025 Dia Global forum issue describes four strategic applications of AI-powered clinical trial feasibility and forecasting, which tells me the category has moved past pilot projects and into routine planning. Teams that pair predictive models with human operational judgment catch protocol-site mismatches earlier; teams that treat the model as a verdict tend to over-trust a black box.

Key takeaways

• Predictive analytics enrolment models use historical site performance, real-world data, and protocol criteria to forecast recruitment before activation.
• AI supports go/no-go decisions by quantifying site feasibility, amendment risk, and competitive overlap; it does not make the final call.
• A data-driven feasibility assessment should cover six pillars: patient population, site capacity, operational burden, regulatory path, competitive landscape, and financial viability.
• Treat AI outputs as inputs to human decision-making, not as guarantees of trial success.
• If your trial is early-stage or your protocol is still fluid, you may not need an AI feasibility platform yet.

What Is AI-Driven Predictive Analytics in Clinical Trial Feasibility?

AI-driven predictive analytics in clinical trial feasibility means applying machine learning models to historical site performance, real-world patient data, and protocol design features to forecast whether a trial can recruit and retain its target population before the first site is activated. It shifts feasibility from a manual, relationship-based exercise to a pattern-recognition exercise grounded in data.

In practice, this looks like ingesting a protocol’s inclusion/exclusion criteria, comparing them against de-identified patient volumes from electronic health records or claims data, and layering on a site’s past enrolment speed for similar indications. The output is a probability distribution—how many patients per month, how many sites needed, how long to full enrolment—rather than a single promise. That distinction matters because feasibility is fundamentally a forecasting problem, not an accounting problem.

How Are AI Models Reshaping Clinical Trial Go/No-Go Decisions?

AI models reshape go/no-go decisions by converting site questionnaires and protocol text into risk scores—enrolment probability, amendment likelihood, and competitive overlap—so sponsors can compare sites and protocols on the same evidence base. The model does not issue the go/no-go verdict; it gives the investment committee a shared, citable starting point.

I have seen teams kill a trial in the feasibility phase because the model showed three competing oncology studies already drawing from the same site network. Without that signal, they would have opened sites, burned budget, and discovered the enrolment ceiling only after first patient in. Medidata frames this same shift as data-driven study decisions built on clinical trial analytics, where historical study performance informs whether to proceed.

The risk is anchoring. A model might give a site a high score because it enrolled well three years ago, while missing that the principal investigator has since left or the site’s patient population has shifted. I treat the model score as one input, not the decision.

What Does Predictive Modeling for Trial Success Actually Measure?

Predictive modeling for trial success measures how protocol eligibility criteria, geographic site density, and historical enrolment rates combine to predict patient accrual, dropout, and protocol deviation risk before the first patient is enrolled. The algorithms weigh structured data—such as inclusion/exclusion complexity—against unstructured signals like site feasibility survey responses.

Common inputs include:

• Eligibility criteria complexity: narrow age windows, rare biomarker requirements, or extensive washout periods shrink the addressable pool.
• Site historical enrolment: average patients per month in comparable indications.
• Geographic density: patient concentration within travel distance of candidate sites.
• Protocol burden: visit frequency, invasive procedures, and length of stay correlate with dropout.
• Competitive landscape: overlapping trials recruiting from the same sites and patient pools.

No algorithm can tell you whether your drug works. It can only tell you whether you are likely to find and keep the patients needed to test it.

Where Does AI Fit in a Data-Driven Feasibility Assessment?

A data-driven feasibility assessment should run across six pillars—patient population, site capacity, operational burden, regulatory path, competitive landscape, and financial viability—with AI handling the pattern matching and humans owning the judgment calls. This is the framework behind Clinical Trial OS, which delivers a six-pillar feasibility assessment and go/no-go verdict in hours, every number cited to its public source.

This framework forces a team to separate what the data says from what the team hopes is true.

What Are the Limitations of AI in Feasibility?

AI in feasibility fails when the training data reflects past site optimism, when protocol amendments change eligibility mid-study, or when the model cannot explain why it flagged a site as high risk. Predictive analytics reduces uncertainty; it does not eliminate it, and it cannot compensate for a protocol that is scientifically sound but operationally impossible.

Data quality is the biggest constraint. If a site’s historical enrolment numbers were self-reported and inflated, the model learns fiction. Regulatory change is another blind spot: a model trained on 2024 submission patterns may not anticipate new FDA or ICH expectations in 2026. I cover the current regulatory environment in more detail in Navigating the 2026 Regulatory Landscape: Key FDA and ICH Updates for Clinical Trials.

How Do You Integrate AI Tools Into Your Clinical Operations Workflow?

Integrating AI into clinical operations means connecting the feasibility model to the systems teams already use—CTMS, EDC, and site relationship management—so that a risk flag triggers a workflow, not just a report. The goal is to make feasibility a recurring checkpoint, not a one-time gate before site selection.

A practical rollout looks like this:

1. Run a baseline feasibility assessment on the current protocol.
2. Flag any site or pillar scoring below a pre-agreed threshold.
3. Assign an owner to investigate each flag—usually the CRA or feasibility lead.
4. Re-run the assessment after protocol amendments or site onboarding.
5. Log the final go/no-go rationale alongside the model outputs for audit.

This mirrors the logic behind risk-based monitoring: monitor where the risk is highest, not where it is easiest to look.

How Should You Evaluate AI-Powered Feasibility Platforms?

Evaluating an AI-powered feasibility platform comes down to whether its outputs are traceable, current, and actionable: can you see the public source behind every number, does the model update when protocols change, and does it fit inside your existing site-selection workflow? If the vendor cannot show its work, the platform is a black box wearing a clinical operations label.

Use this checklist before signing:

• Source transparency: Every forecast cites a public or verifiable data source.
• Update cadence: Model refreshes when protocols, sites, or competitive trials change.
• Explainability: You can see which features drove a high or low score.
• Workflow fit: Outputs feed into your CTMS or site-selection process, not a standalone dashboard.
• No success guarantees: The vendor frames AI as decision support, not outcome assurance.

What Is the Future of Clinical Trial Planning With AI?

The future of clinical trial planning with AI lies in adaptive feasibility—continuously re-scoring sites and protocols as enrolment data arrives, rather than treating feasibility as a static pre-study exercise. Regulatory guidance such as ICH E6(R3) is already moving toward risk-based quality management, which makes predictive feasibility a compliance-relevant activity, not just an efficiency play. I cover that shift in Navigating ICH E6(R3) in 2026: A Sponsor's Guide to Risk-Based Quality Management.

I also expect closer integration between feasibility and site selection, where predictive models automatically rank sites for a specific protocol rather than requiring a manual feasibility survey each time. That said, the most important skill in 2026 is still knowing when to disregard the model and trust the site team on the ground.

If you are weighing a go/no-go decision on a protocol, our six-pillar feasibility assessment delivers a cited verdict in hours. Learn more about Clinical Trial OS.

FAQ

Does AI replace the go/no-go decision?

No. AI predicts enrolment and risk, but the go/no-go decision remains a human judgment that weighs strategy, budget, and scientific rationale alongside the model’s output.

Can predictive analytics reduce clinical trial failure rates?

It can reduce failures caused by poor feasibility—under-recruitment, site dropout, and protocol amendments—by identifying those risks before sites are activated. It cannot prevent failures caused by efficacy or safety readouts.

What data do AI feasibility models need?

They typically need protocol eligibility criteria, historical site enrolment, real-world patient volumes, geographic data, and competitive trial information. The quality of the prediction depends on the quality of these inputs.

Is AI feasibility assessment regulated?

Not as a standalone product category today, but the trials it informs are regulated. Sponsors should maintain documentation showing how feasibility decisions were made, especially as ICH E6(R3) emphasizes risk-based quality management.

Do early-stage biotechs need AI feasibility tools yet?

Not necessarily. If you have one protocol and a small site list, a spreadsheet and expert judgment may suffice. The value increases as you scale to multiple sites, regions, or competing protocols.